Mechlorethamine Hydrochloride Gel in the Treatment of Mycosis Fungoides–Type Cutaneous T-Cell Lymphoma (MF-CTCL): A Focus on Patient Selection and Special Considerations

References

• Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768–3785. doi:10.1182/blood-2004-09-3502
   PubMed Web of Science ®Google Scholar
• Tarabadkar ES, Shinohara MM. Skin directed therapy in cutaneous T-cell lymphoma. Front Oncol. 2019;9:260. doi:10.3389/fonc.2019.00260
   PubMed Web of Science ®Google Scholar
• Haserick JR, Richardson JH, Grant DJ. Remission of lesions in mycosis fungoides following topical application of nitrogen mustard. Cleve Clin Q. 1983;50(2):91–95. doi:10.3949/ccjm.50.2.91
   PubMedGoogle Scholar
• Singh RK, Kumar S, Prasad DN, Bhardwaj TR. Therapeutic journery of nitrogen mustard as alkylating anticancer agents: historic to future perspectives. Eur J Med Chem. 2018;151:401–433. doi:10.1016/j.ejmech.2018.04.001
   PubMed Web of Science ®Google Scholar
• Ramsay DL, Halperin PS, Zeleniuch-Jacquotte A. Topical mechlorethamine therapy for early stage mycosis fungoides. J Amer Acad Dermat. 1988;19(4):684–691. doi:10.1016/S0190-9622(88)70223-6
   PubMed Web of Science ®Google Scholar
• Chang YT, Ignatova D, Hoetzenecker W, Pascolo S, Fassnacht C, Guenova E. Increased chlormethine-induced DNA double-stranded breaks in malignant T cells from mycosis fungoides skin lesions. JID Innov. 2022;2(1):100069. doi:10.1016/j.xjidi.2021.100069
   PubMedGoogle Scholar
• Ramsay DL, Meller JA, Zackheim HS. Topical treatment of early cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 1995;9(5):1031–1056. doi:10.1016/S0889-8588(18)30057-1
   PubMed Web of Science ®Google Scholar
• Kim YH. Management with topical nitrogen mustard in mycosis fungoides. Dermatol Ther. 2003;16(4):288–298. doi:10.1111/j.1396-0296.2003.01640.x
   PubMedGoogle Scholar
• Lessin SR, Duvic M, Guitart J, et al. Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides. JAMA Dermatol. 2013;149(1):25–32. doi:10.1001/2013.jamadermatol.541
   PubMed Web of Science ®Google Scholar
• Van Scott EJ. Complete regressions of mycosis fungoides with topical mechlorethamine hydrochloride. JAMA. 1972;222(9):1172. doi:10.1001/jama.1972.03210090052026
   PubMed Web of Science ®Google Scholar
• Van Scott EJ, Kalmanson JD. Complete remissions of mycosis fungoides lymphoma induced by topical nitrogen mustard (HN2). Control of delayed hypersensitivity to HN2 by desensitization and by induction of specific immunologic tolerance. Cancer. 1973;32(1):18–30. doi:10.1002/1097-0142(197307)32:1<18::AID-CNCR2820320103>3.0.CO;2-Q
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Van Scott EJ, Wallner PE, Johnson WC. A 10-year experience with topical mechlorethamine for mycosis fungoides: comparison with patients treated by total-skin electron-beam radiation therapy. Cancer Treat Rep. 1979;63(4):681–689.
   PubMedGoogle Scholar
• Kim YH, Martinez G, Varghese A, Hoppe RT. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003;139(2):165–173. doi:10.1001/archderm.139.2.165
   PubMedGoogle Scholar
• Querfeld C, Scarisbrick JJ, Assaf C, et al. Post hoc analysis of a randomized, controlled, phase 2 study to assess response rates with chlormethine/mechlorethamine gel in patients with stage IA-IIA mycosis fungoides. Dermatology. 2022;238(2):347–357. doi:10.1159/000516138
   PubMed Web of Science ®Google Scholar
• Papadavid E, Koumourtzis M, Nikolaou V, et al. Chlormethine gel is effective for the treatment of skin lesions in patients with early- and late-stage mycosis fungoides in clinical practice. J Eur Acad Dermatol Venereol. 2022;36(10):1751–1757. doi:10.1111/jdv.18183
   PubMed Web of Science ®Google Scholar
• Alexander-Savino CV, Chung CG, Gilmore ES, Carroll SM, Poligone B. Randomized mechlorethamine/chlormethine induced dermatitis assessment study (MIDAS) establishes benefit of topical triamcinolone 0.1% ointment cotreatment in mycosis fungoides. Dermatol Ther. 2022;12(3):643–654. doi:10.1007/s13555-022-00681-6
   Web of Science ®Google Scholar
• Helsinn Therapeutics. Valchlor (mechloretheamine) gel 0.016% [package insert]. U.S. Food and Drug Administration website; 2013. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/202317lbl.pdf. Accessed July 10, 2022.
   Google Scholar
• Kim EJ, Guitart J, Querfeld C, et al. The PROVe study: US real-world experience with chlormethine/mechlorethamine gel in combination with other therapies for patients with mycosis fungoides cutaneous T-cell lymphoma. Am J Clin Dermatol. 2021;22(3):407–414. doi:10.1007/s40257-021-00591-x
   PubMed Web of Science ®Google Scholar
• Wehkamp U, Jost M, Gosmann J, Grote U, Bernard M, Stadler R. Management of chlormethine gel treatment in mycosis fungoides patients in two German skin lymphoma centers. J Dtsch Dermatol Ges. 2021;19(7):1057–1059.
   Web of Science ®Google Scholar
• Geskin LJ, Bagot M, Hodak E, Kim EJ. Chlormethine gel for the treatment of skin lesions in all stages of mycosis fungoides cutaneous T-cell lymphoma: a narrative review and international experience. Dermatol Ther. 2021;11(4):1085–1106. doi:10.1007/s13555-021-00539-3
   PubMed Web of Science ®Google Scholar
• Assaf C, Booken N, Dippel E, et al. The optimal use of chlormethine gel for mycosis fungoides: an expert consensus from Germany, Austria and Switzerland (DACH region). J Dtsch Dermatol Ges. 2022;20(5):579–586.
   Web of Science ®Google Scholar
• Reddy VB, Ramsay D, Garcia JA, Kamino H. Atypical cutaneous changes after topical treatment with nitrogen mustard in patients with mycosis fungoides. Am J Dermatopathol. 1996;18(1):19–23. doi:10.1097/00000372-199602000-00003
   PubMed Web of Science ®Google Scholar
• Povirk LF, Shuker DE. DNA damage and mutagenesis induced by nitrogen mustards. Mutat Res. 1994;318(3):205–226. doi:10.1016/0165-1110(94)90015-9
   PubMed Web of Science ®Google Scholar
• Vonderheid EC, Tan ET, Kantor AF, Shrager L, Micaily B, Van Scott EJ. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Amer Acad Dermatol. 1989;20(3):416–428. doi:10.1016/S0190-9622(89)70051-7
   PubMed Web of Science ®Google Scholar
• Lindahl LM, Fenger-Gron M, Iversen L. Secondary cancers, comorbidities and mortality associated with nitrogen mustard therapy in patients with mycosis fungoides: a 30-year population-based cohort study. Br J Dermatol. 2014;170(3):699–704. doi:10.1111/bjd.12620
   PubMed Web of Science ®Google Scholar
• Querfeld C, Geskin LJ, Kim EJ, et al. Lack of systemic absorption of topical mechlorethamine gel in patients with mycosis fungoides cutaneous T-cell lymphoma. J Invest Dermatol. 2021;141(6):1601–1604 e1602. doi:10.1016/j.jid.2020.12.009
   PubMed Web of Science ®Google Scholar
• Laghi A, Franceschini C, Mandel VD, et al. Topical chlormethine gel in the treatment of mycosis fungoides: a single-center real-life experience and systematic review of the literature. Dermatol Ther. 2022;35:e15683. doi:10.1111/dth.15683
   PubMed Web of Science ®Google Scholar
• NCCN clinical practice guidelines in oncology (NCCN guidelines), primary cutaneous lymphomas. National Comprehensive Cancer Network; 2022. Available from: https://www.nccn.org/professionals/physician_gls/pdf/primary_cutaneous.pdf. Accessed October 07, 2022.
   Google Scholar
• Kim EJ, Geskin L, Guitart J, et al. Real-world experience with mechlorethamine gel in patients with mycosis fungoides-cutaneous lymphoma: preliminary findings from a prospective observational study. J Amer Acad Dermatol. 2020;83(3):928–930. doi:10.1016/j.jaad.2019.12.070
   PubMed Web of Science ®Google Scholar
• Lampadaki K, Koumourtzis M, Karagianni F, Marinos L, Papadavid E. Chlormethine gel in combination with other therapies in the treatment of patients with mycosis fungoides cutaneous T cell lymphoma: three case reports. Adv Ther. 2021;38(6):3455–3464. doi:10.1007/s12325-021-01721-x
   PubMed Web of Science ®Google Scholar
• Chinn DM, Chow S, Kim YH, Hoppe RT. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys. 1999;43(5):951–958. doi:10.1016/S0360-3016(98)00517-3
   PubMed Web of Science ®Google Scholar
• Jennings T, Duffy R, Gochoco A, et al. Valchlor maintenance therapy for patients with mycosis fungoides who received low dose total skin electron beam treatment. Chin Clin Oncol. 2019;8(1):13. doi:10.21037/cco.2018.10.01
   PubMed Web of Science ®Google Scholar
• Demierre MF, Tien A, Miller D. Health-related quality-of-life assessment in patients with cutaneous T-cell lymphoma. Arch Dermatol. 2005;141(3):325–330. doi:10.1001/archderm.141.3.325
   PubMed Web of Science ®Google Scholar
• Molloy K, Jonak C, Woei AJF, et al. Characteristics associated with significantly worse quality of life in mycosis fungoides/Sezary syndrome from the Prospective Cutaneous Lymphoma International Prognostic Index (PROCLIPI) study. Br J Dermatol. 2020;182(3):770–779. doi:10.1111/bjd.18089
   PubMed Web of Science ®Google Scholar
• Herbosa CM, Semenov YR, Rosenberg AR, Mehta-Shah N, Musiek AC. Clinical severity measures and quality-of-life burden in patients with mycosis fungoides and Sezary syndrome: comparison of generic and dermatology-specific instruments. J Eur Acad Dermatol Venereol. 2020;34(5):995–1003. doi:10.1111/jdv.16021
   PubMed Web of Science ®Google Scholar
• Shinohara MM, Mahurin HM, Tarabadkar E, et al. Health-related quality of life in cutaneous T-cell lymphoma: a cross-sectional survey study. Skin Health Dis. 2021;1(3):e45. doi:10.1002/ski2.45
   PubMedGoogle Scholar
• VALCHLOR. Micromedex, RED BOOK. Available from: www-micromedexsolutions-com. Accessed October 22, 2022.
   Google Scholar
• Xia FD, Ferket BS, Huang V, Stern RS, Wu PA. Local radiation and phototherapy are the most cost-effective treatments for stage IA mycosis fungoides: a comparative decision analysis model in the United States. J Am Acad Dermatol. 2019;80(2):485–492.e484. doi:10.1016/j.jaad.2018.07.040
   PubMed Web of Science ®Google Scholar
• Lehman JS, Cook-Norris RH, Weed BR, et al. Folliculotropic mycosis fungoides: single-center study and systematic review. Arch Dermatol. 2010;146(6):607–613. doi:10.1001/archdermatol.2010.101
   PubMedGoogle Scholar
• Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/Sézary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol. 2010;28(31):4730–4739. doi:10.1200/JCO.2009.27.7665
   PubMed Web of Science ®Google Scholar
• Charli-Joseph Y, Kashani-Sabet M, McCalmont TH, et al. Association of a proposed new staging system for folliculotropic mycosis fungoides with prognostic variables in a US cohort. JAMA Dermatol. 2021;157(2):157–165. doi:10.1001/jamadermatol.2020.4372
   PubMed Web of Science ®Google Scholar
• Nikolaou V, Sachlas A, Papadavid E, et al. Phototherapy as a first-line treatment for early-stage mycosis fungoides: the results of a large retrospective analysis. Photodermatol Photoimmunol Photomed. 2018;34(5):307–313. doi:10.1111/phpp.12383
   PubMed Web of Science ®Google Scholar
• Huang AH, Kwatra SG, Khanna R, Semenov YR, Okoye GA, Sweren RJ. Racial disparities in the clinical presentation and prognosis of patients with mycosis fungoides. J Natl Med Assoc. 2019;111(6):633–639. doi:10.1016/j.jnma.2019.08.006
   PubMed Web of Science ®Google Scholar
• Wu JH, Cohen BA, Sweren RJ. Mycosis fungoides in pediatric patients: clinical features, diagnostic challenges, and advances in therapeutic management. Pediatr Dermatol. 2020;37(1):18–28. doi:10.1111/pde.14026
   PubMed Web of Science ®Google Scholar
• Kothari R, Szepietowski JC, Bagot M, et al. Mycosis fungoides in pediatric population: comprehensive review on epidemiology, clinical presentation, and management. Int J Dermatol. 2022. doi:10.1111/ijd.16098
   Web of Science ®Google Scholar
• Danforth CH, Center E. Nitrogen mustard as a teratogenic agent in the mouse. Proc Soc Exp Biol Med. 1954;86(4):705–707. doi:10.3181/00379727-86-21207
   PubMed Web of Science ®Google Scholar